SCTX
Scribe Therapeutics, Inc.CIK 0001853921 · SIC 2836 · Biological Products
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade SCTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Scribe Therapeutics prices $128.7M IPO at $15/share; concurrent Sanofi placement adds $7.5M
6 material changes detected. Sign up free to read the summary.
Scribe Therapeutics finalizes IPO terms: $14.00 midpoint, $96.2M net proceeds, cash runway to H1 2029
5 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Scribe Therapeutics files for IPO to fund CRISPR cardiovascular therapies; terms not yet set
8 material changes detected. Sign up free to read the summary.
Latest financial statements
From 10-Q filed Sep 2, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Statements of Operations and Comprehensive Loss (Unaudited)
(In thousands, except share and per share amounts)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue | 1,918 | 4,898 | 4,151 | 22,023 |
| Operating expenses: | ||||
| Research and development | 8,823 | 13,884 | 20,128 | 29,876 |
| General and administrative | 2,490 | 2,641 | 5,844 | 9,332 |
| Total operating expenses | 11,313 | 16,525 | 25,972 | 39,208 |
| Loss from operations | (9,395) | (11,627) | (21,821) | (17,185) |
| Interest income and other income (expense), net | 383 | 880 | 898 | 1,944 |
| Interest expense | (276) | (598) | (875) | (1,197) |
| Change in fair value of Convertible Note | 3,023 | 730 | (1,585) | 2,083 |
| Net loss before provision for income taxes | (6,265) | (10,615) | (23,383) | (14,355) |
| (Provision for) / benefit from income tax | (212) | 712 | (441) | 1,027 |
| Net loss | (6,477) | (9,903) | (23,824) | (13,328) |
| Other comprehensive loss: | ||||
| Net unrealized loss on available-for-sale investments | (2) | (36) | (37) | (93) |
| Net comprehensive loss | (6,479) | (9,939) | (23,861) | (13,421) |
| Net loss per share attributable to common stockholders, basic and diluted | (2.62) | (4.08) | (9.65) | (5.50) |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 2,475,898 | 2,429,130 | 2,468,343 | 2,423,315 |
Condensed Balance Sheets (Unaudited)
(In thousands, except share and per share amounts)
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | 35,586 | 12,796 |
| Short-term investments | 7,423 | 45,167 |
| Receivable from collaboration partners | 1,107 | 7,092 |
| Prepaid expenses and other current assets | 989 | 1,879 |
| Total current assets | 45,105 | 66,934 |
| Operating lease right-of-use asset | 2,782 | 3,064 |
| Property and equipment, net | 5,755 | 7,008 |
| Restricted cash | 675 | 675 |
| Other long-term assets | 3,610 | 538 |
| Total assets | 57,927 | 78,219 |
| Liabilities, redeemable convertible preferred stock, and stockholders’ deficit | ||
| Current liabilities: | ||
| Accounts payable | 2,771 | 4,566 |
| Accrued expenses and other current liabilities | 7,183 | 6,405 |
| Accrued license fees | 2,100 | 375 |
| Deferred revenue, current | 27,475 | 21,087 |
| Convertible Note | 37,799 | 35,339 |
| Operating lease liabilities, current portion | 1,369 | 1,285 |
| Total current liabilities | 78,697 | 69,057 |
| Operating lease liabilities, net of current portion | 4,102 | 4,804 |
| Other non-current liabilities | 7,920 | 7,485 |
| Deferred revenue, non-current | 11,698 | 19,936 |
| Total liabilities | 102,417 | 101,282 |
| Redeemable convertible preferred stock, $0.001 par value; 29,182,118 shares authorized, and 4,915,299 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively; liquidation preference of $120,705 as of June 30, 2026 and December 31, 2025 | 120,356 | 120,356 |
| Common stock, $0.001 par value, 52,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 2,485,234 and 2,451,167 shares issued and outstanding as of June 30, 2026 and December 31, 2025 | 14 | 14 |
| Additional paid-in capital | 16,673 | 14,239 |
| Accumulated deficit | (181,531) | (157,707) |
| Accumulated other comprehensive income | (2) | 35 |
| Total stockholders’ deficit | (164,846) | (143,419) |
| Total liabilities, preferred stock, and stockholders’ deficit | 57,927 | 78,219 |
Condensed Statements of Cash Flows (Unaudited)
(In thousands)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | (23,824) | (13,328) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Depreciation expense | 1,277 | 1,468 |
| Loss on disposal of equipment | 4 | 5 |
| Stock-based compensation expense | 2,197 | 1,347 |
| Interest expense | 875 | 1,197 |
| Change in fair value of convertible note | 1,585 | (2,083) |
| Net amortization/accretion on investment securities | 210 | 474 |
| Amortization of right-of-use asset | 281 | 230 |
| Expensed deferred offering costs | — | 3,583 |
| Cash received from government grants | 3,830 | — |
| Changes in operating assets and liabilities: | ||
| Receivables from collaboration partners | 5,985 | 292 |
| Prepaid expenses and other current assets | 890 | 445 |
| Other long-term assets | (520) | (209) |
| Accounts payable | (2,139) | 1,193 |
| Deferred revenue | (1,850) | (11,880) |
| Accrued license fees | 1,725 | (750) |
| Accruals and other current liabilities | (3,236) | (479) |
| Operating lease liabilities | (616) | (531) |
| Other non-current liabilities | 434 | (1,226) |
| Net cash used in operating activities | (12,892) | (20,252) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (27) | (930) |
| Maturities of investments | 42,339 | 56,231 |
| Purchases of investments | (4,842) | (31,722) |
| Net cash provided by investing activities | 37,470 | 23,579 |
| Cash flows from financing activities | ||
| Proceeds from exercise of stock options | 238 | 51 |
| Payments of deferred offering costs | (2,026) | — |
| Net cash (used in) / provided by financing activities | (1,788) | 51 |
| Net change in cash, cash equivalents and restricted cash | 22,790 | 3,378 |
| Cash, cash equivalents and restricted cash, at the beginning of the period | 13,471 | 13,277 |
| Cash, cash equivalents and restricted cash, at the end of the period | 36,261 | 16,655 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Unpaid fixed asset acquisitions | — | 306 |
| Deferred offering costs related to initial public offering included in accounts payable and accrued expenses and other current liabilities | 975 | — |
Amounts as printed on the EDGAR/iXBRL face — (In thousands, except share and per share amounts); (In thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗